Found: 7
Select item for more details and to access through your institution.
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
- Published in:
- Seminars in Immunopathology, 2017, v. 39, n. 3, p. 327, doi. 10.1007/s00281-016-0613-x
- By:
- Publication type:
- Article
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82).
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11065-0
- By:
- Publication type:
- Article
Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59.
- Published in:
- Biomedicines, 2022, v. 10, n. 5, p. 1211, doi. 10.3390/biomedicines10051211
- By:
- Publication type:
- Article
Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Toxicité gastro-intestinale induite par les inhibiteurs dé checkpoint immunitaire de type anticorps anti- CTLA-4 et anti-PD-1/PD-L1.
- Published in:
- Hépato-Gastro & Oncologie Digestive, 2018, v. 25, n. 3, p. 256, doi. 10.1684/hpg.2018.1586
- By:
- Publication type:
- Article
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.
- Published in:
- Journal of Crohn's & Colitis, 2017, v. 11, n. 10, p. 1238, doi. 10.1093/ecco-jcc/jjx081
- By:
- Publication type:
- Article
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-16079-x
- By:
- Publication type:
- Article